Website

Bio

Fiona has over 25 years experience in healthcare, biotechnology and venture capital. She was the co-founder and Chief Executive of the anti-infectives company Novacta Biosystems until the end of 2007. Before this Fiona was Chief Executive of Pharminox Limited, Novarticulate BV and Metris Therapeutics Limited. She worked in venture capital for Rothschilds and J&J Development Corporation in the mid-90s specialising in the strategic development and management of early-stage companies. Fiona’s early career was in business development at CRC Technology Limited and at Celltech plc.

Sessions

Facebook Linkin Twitter Website

Bio

After a 30-year stint as a professional editor and journalist that ended on April 30, 2016, Mr Narayanan Suresh formally joined ABLE on May 2, 2016 as its COO. The association was founded in 2003 to represent the interests of the fast-growing biotechnology industry.

For more than 13 years as the Editor of BioSpectrum, Mr N Suresh has worked closely with the biotech sector. Therefore, his rich experience and knowledge are expected to benefit the industry in due course of time. From being  a neutral observer to the biotech industry insider, his second innings now allows him to continue the association with sector.

The journalistic journey of Mr N Suresh began exactly 30 years ago in May 1996 when he joined the Times of India in New Delhi as their first-ever Exclusive Science Reporter, after a grueling 10-month training in Social Journalism with the Times Center for Media Studies( then called The Times Research Foundation School for Social Journalism) in the very first batch.

From a writer, in 1997 he moved to CyberMedia as the Associate Editor of DATAQUEST, the country’s leading IT publication, and it was a transformation, from being just a writer to an Editor-Manager. “The Chairman of Cybermedia, Mr Pradeep Gupta as well as one of its then Directors, Mr Shyam Malhotra believed in my capabilities and gave me many challenging roles that involved creating strong publication brands, says Suresh nostalgically.

At CyberMedia, he was later involved in launching and building the BioSpectrum magazine, the only source of information for biotech industry back then. Later, he also moved on with the brand to MM Activ Sci-Tech Communications when it was acquired by the later. During his long stint as the Editor, he managed and edited various publications within these publishing houses.

Sessions

Linkin Website

Bio

Dr James Wilkie is Director of Enterprise & Innovation for the University of Birmingham, CEO for Alta Innovations (the technology transfer company for the University of Birmingham), and CEO of the Birmingham Research Park, which houses two incubators including the BioHub Birmingham®, a fully equipped life sciences incubator.

Sessions

Linkin Twitter Website

Bio

Prabhu Mishra , CEO & Founder- StemGenn Therapeutics, President – StemMax Research & Therapeutics Pvt Ltd. Co-Founder- Global StemGenn Therapy & Research PVT ltd. Ex- Secretary General – Stem cell society (India) , Founder President – Anti ageing Foundation, Vice President- Indian Stem cell study Group.

Advisor: Regenerative Therapy- IORA, Stem cell committee Head – ISAR Delhi Chapter , Reviewer – Journal of cutaneous and aesthetic surgery. Associate Editor – Indian journal of stem cell Therapy. Collaborator with SumanDeep Vidyapeeth University , InDNA LIFESCIENCES. Member ,International society of Cellular Therapy, American society of cell and Gene Therapy, International society of stem cell Research. Founded- Indian Regenerative and Aesthetic science study group.

Given consultation to more than 15 stem cell facilities. Prabhu Mishra have set up 8 stem cells centre across country and Internationally.

Prabhu Mishra, welcomes you to StemGenn Therapeutics, a leading stem cell therapy & regenerative medicine services company, hurling the stem cell revolution in India. It is dedicated to the development and commercialisation of cellular therapies and stem cell research in India. Prabhu Mishra works to develop strategic alliances and to implement national and international projects for the mission of advancing regenerative medicine and stem cell therapy.

StemGenn Mission is contribute to human health by enabling technologies using Regenerative Medicine. Aims to provide treatment option in Aesthetic Medicine, Anti Ageing , Infertility, Cosmetic Gynaecology , Wellness , Life style Diseases & Auto immune diseases.

StemGenn started world class training module in Stem Cell & Regenerative Medicine , Bio Identical Hormones , Aesthetic Medicine , Cosmetic Gynaecology & Anti Ageing .

Prabhu Mishra works to develop strategic alliances and to implement national and international projects for the mission of advancing regenerative medicine and stem cell therapy. Prabhu’s personal experience with life-changing cellular therapies and adult stem cell transplant programme ignited his passion to be involved with an innovative new area of medicine bringing together the industry leaders in regulatory, science, medicine, safety and ethics via a association model to yield the best possible patient outcomes.
 Prabhu participates in the organizational business strategy, membership procurement, marketing, international and domestic conference and event planning/implementation, financial decisions and budgeting. Prabhu works with the GIOSTAR team to develop compelling business plans to optimize strategy, present a competitive edge, and to articulate the client’s competitive position. Prabhu creates financial reports for Executive Summaries such as profit/loss statements which include sales forecasts, personnel and operating costs, break even analysis and cash flow projections.

Specialties Area: Blood Bank & Transfusion Medicine , Cord blood Banking, Stem cells (adipose, dental pulp, peripheral blood, limbal) Plastic Surgery, General Surgery(Abdominal Wall Reconstruction, Hernia Repair, Breast Surgery, Wound Care and Trauma), Orthopedics, Spine , Sports Medicine, Neurosurgery, Trauma, Colon Rectal, Cardiac, Perfusion, Dental, Oral Max , Vascular, BMA, Bone Marrow Aspirate, PRP, Platelet Rich Plasma, Stem Cell, Tissue Regeneration and Regenerative Medicine.

Sessions

Linkin Website

Bio

Professor S.S. Vasan is a Senior Business Development Manager (Research & Technical Microbiology Services & Innovation) in a new executive agency of the Department of Health, formed by the merger of Health Protection Agency with ~100 sender organisations such as National Treatment Agency, Public Health Observatories, UK National Screening Committee and NHS cancer and non-cancer screening programmes, Cancer Registries, Quality Assurance Reference Centres, Strategic Health Authorities, Specialised Commissioners, and parts of the Department of Health, including Public Health Marketing.

It aims to help bring about fundamental improvements in the public’s health and wellbeing by focusing its energies on five key priorities:

1. helping people to live longer by reducing preventable deaths from conditions such as heart disease, stroke, cancer and liver disease

2. increasing healthy life expectancy by tackling conditions which place a burden on many lives, such as anxiety, depression and back pain

3. protecting the population from infectious diseases and environmental hazards, including emerging risks and the growing problem of antimicrobial resistance

4. supporting families to give children the best start in life, through working with health visitors, Family Nurse Partnerships and the Troubled Families Programme

5. helping employers to facilitate and encourage their staff to make healthy choices.

Over the last two decades, I have gained expertise and experience in these areas:
– Biosafety, biodefence and biosecurity
– Biotechnology and bioengineerng
– GMOs, and their applications in health and agriculture
– Infectious diseases, especially medical entomology
– Microbiology services including bioprocessing and bioseparation
– New business development and innovation, especially for life sciences, bio/pharma and medical products.

Sessions

Website

Bio

Hitesh Thakrar is a Partner of Syncona Investment Management Ltd. He is an experienced investor in the sector, having spent over 20 years investing in public global equities in the life sciences, technology and the innovation sectors.

He has worked at various institutions in equity research and Fund Management from ADIA, the sovereign wealth Fund of Abu Dhabi, JP Morgan, Aviva Group, Dresdner Bank and New Star Asset Management. He has a strong track record, rated AA manager and was also a top 1 percentile manager in global equities. He is on the Board of Desktop Genetics, a CRISPR IP library company, backed by Illumina and is an angel investor in early stage Innovation companies. He is also on the Investment Committee of the LBA Scale Up Innovation Fund.

Hitesh holds a degree in Chemistry from Kings College, London, MBA from Cranfield University and CFA, the American Association of Investment Analysts.

Sessions

Website

Bio

Andrew Fried is IBM Life Sciences Leader for Europe.

Andrew helps clients address industry imperatives and save lives through the power of cognitive insights.  He works with clients to advance the next generation of discovery and development, acting on insights to drive value, enhance relationships across the ecosystem and empowering people to make better decisions.

Prior to transferring to Europe in July 2015, Andrew was IBM’s Life Sciences Leader for China. While in China Andrew worked with many leading multi-national companies and several Chinese Life Sciences companies who were leaders in their respective segment.

Before joining IBM in 2000, Andrew had a successful 14-year career with a leading strategy consulting company.  He graduated from Melbourne University with a Bachelor of Arts, and Monash University (Melbourne, Australia) with a Bachelor of Business.  Andrew has a Masters of Business Administration from the International University of Japan and is a Fellow of the Financial Services Institute of Australasia. He was a three-term board member on a government enterprise with assets of over $350M. He was a founding director of a successful dot.com start-up in the early 2000s.

Andrew is an advocate of sport and fitness as a gateway to good health.  He is passionate about the role of genomics in identifying both the cause of disease and personalized solutions.

Sessions

Linkin Twitter Website

Bio

Phillip D’Costa is an experienced Partner specialising in commercial, fraud, IT and financial services dispute resolution, arbitration and ADR. Phillip has been ranked as a leading individual for UK and India dispute resolution in Chambers Global 2014 and foreign expert in Chambers Global 2015.

Key areas of practice:
• Commercial – Litigation & Arbitration, jurisdictional issues, partnership/LLP, contractual claims, shareholders, Technology, director’s duties and insolvency;
• Civil Fraud – Company investigations, restitution claims, misrepresentation, asset tracing, freezing & recovery, supply chain fraud, employee fraud;
• Financial Services & Regulatory – Securitisation, asset finance, leasing, share fraud, miss-selling, derivatives and structured products, money laundering, regulatory, compliance;• Has a particular interest in arbitration and transactional work involving India and has advised on a number of disputes and transactions involving India or Indian Companies, Families and Individuals.

Specialities:
Civil Fraud – Company investigations, Freezing Orders, Fraud investigation and Asset tracing.

Commercial – Litigation & International arbitration, jurisdictional issues, partnership and LLP advice and disputes, IT & IP disputes, contractual claims, shareholders disputes, Asset Finance & Leasing, Cross border transactions, Insolvency and Licensing.

Financial Services & Regulatory – miss-selling, money laundering, regulatory, compliance.

Sessions

Linkin Website

Bio

Dr. Villoo Patell is an Academic Entrepreneur who founded Avesthagen in 1998. Avesthagen is globally recognized as a leading systems biology company with a unique model focused on the convergence of food, pharma and population genetics. A convergence that leads to continuous and path-breaking innovations in predictive, preventive, personalized healthcare. Owing to her pioneering work in the field of molecular biology, Dr. Villoo Patell has long-standing professional relationships with individuals, institutions and corporates working in the domain of biotechnology across the world. She is a key member of the Task Force and Vision Group for Biotechnology, instituted by the State Government of Karnataka and founding member of the Association of Biotechnology Led Enterprises (ABLE). Dr. Villoo Patell was Awarded the ‘Officer of the National Order of Merit’ by the President of the French Republic in April 2008.

Dr. Villoo Patell has worked with Dr. Richard Jefferson to initiate the development of pCAMBIA vectors for transformation of crops with both agrobacterium and biolistic methodologies. The pCAMBIA range of vectors, today, are used worldwide by agricultural researchers and the project was funded by the Rockefeller Foundation.
Dr. Villoo Patell has worked with Dr. Richard Jefferson in creating vectors for transformation of rice by both agrobacterium and biolistic technologies. (This was the first start to the creation of pCAMBIA vectors that went on to become used by agricultural researchers in the world.).
Funded by the Rockefeller Foundation.

Sessions